.png)
Montréal, Canada — April 30, 2026, Amplitude Ventures, Canada’s leading precision medicine venture capital firm, announced today that the company is leading a founding round of financing for RIME Therapeutics, a drug discovery company bridging the gap between target identification and actionable chemistry. Rime’s other investors include an undisclosed global strategic investor and CQDM. As part of this financing, Mike Mee, Partner, Amplitude Ventures, will become Chief Executive Officer of RIME Therapeutics.
RIME was most recently recognized with the AbbVie Biotech Innovators Award presented by AbbVie in collaboration with adMare BioInnovations for RIME’s function-first Disruptide platform, using AI-designed probes to systematically find targets that move disease biology. Rime’s screens deliver what novel targets have always lacked: rich, target-specific binding and structure-activity data that turns uncharted pockets into viable drug development programs.
"This financing round marks a pivotal next step for RIME,” said Michael Mee, CEO, RIME Therapeutics, Partner, Amplitude Ventures and Managing Director, Pre-Amp. “Built by Pre-Amp, Amplitude’s venture creation engine, RIME originated as an Amplitude Fellowship venture hypothesis. On the heels of this external validation from AbbVie, we look forward to building the Disruptide platform with a world-class set of founders and advisors, capitalizing on our vibrant ecosystem of local talent and capabilities, and moving towards a differentiated pipeline of medicines for patients."
RIME Therapeutics is an incubated company from Pre-Amp, Amplitude’s company creation engine focused on identifying white space science with high unmet need opportunities and building companies to address them. From venture hypothesis to commercialization, Pre-Amp also originated Stereo Biotherapeutics, a company focused on overcoming the challenge of heterogeneity in solid tumors and other diseases. More than half a dozen innovative life sciences companies have originated from Pre-Amp.
About RIME Therapeutics
RIME Therapeutics is a Montreal-based drug discovery company bridging the gap between target identification and actionable chemistry. Our proprietary function-first Disruptide Platform uses AI-designed probes to systematically scan functional drug pocket space across the intracellular proteome. Integrating human genetics, perturbation biology, and AI, RIME discovers and validates novel intracellular targets while simultaneously delivering functional chemical hits against them. This unified approach accelerates the path from novel biology to actionable chemistry, unlocking first-in-class programs.
RIME was founded in 2025 by Pre-Amp, Amplitude Ventures’ company creation engine, in partnership with leading academic researchers. RIME is the recipient of the 2026 AbbVie Biotech Innovators Award and was part of the 2025 cohort of the Merck Digital Sciences Studio.
To learn more, follow us @RIME Therapeutics or visit rimetherapeutics.com.
About Amplitude Ventures
Amplitude Ventures is a capital catalyst for highly innovative companies at the point of value acceleration. We work with the most promising healthcare companies that share our vision of bringing groundbreaking technologies to patients. Amplitude is building world-class companies in precision medicine and next-generation medical devices.
Since 2012, the Amplitude team has deployed a venture growth model to build companies with world-class management teams and scale them to breakout potential. Partnering with founders globally, the team has used this approach to create, build, and grow companies, resulting in over $6 billion in company value. Follow us @Amplitude Ventures or visit: amplitudevc.com.
Media contact
Karen N. Li
Manager, Marketing and Communications
Amplitude Ventures
kli@amplitudevc.com
-30-
